Other News To Note
Friday, December 7, 2012
Arno Therapeutics Inc., of Flemington, N.J., has identified a new immunohistochemistry technique for identifying activated progesterone receptors in breast cancer tumors that may be predictive of response to treatment with onapristone, an investigational progestin receptor antagonist being developed by Arno that has demonstrated antitumor activity in preclinical and clinical studies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.